PrimRNA AU

PrimRNA AU Pty Ltd is an Australian biotechnology company and a subsidiary of PrimRNA Inc., which is part of the NANO MRNA Co., Ltd. group. The company specializes in the development of mRNA-based regenerative therapies, with a primary focus on orthopedic conditions. Its lead program, RUNX1 mRNA, is a first-in-class disease-modifying treatment for knee osteoarthritis designed to stimulate cartilage repair and regeneration. In early 2026, PrimRNA AU initiated a Phase 1 first-in-human clinical trial in Australia, marking the world's first intra-articular administration of an mRNA therapeutic for osteoarthritis. The company utilizes a proprietary mRNA drug discovery platform and advanced drug delivery systems to target previously undruggable pathways in chronic degenerative diseases. Through strategic cross-border collaboration between Japan and Australia, PrimRNA AU aims to advance innovative RNA medicines from early-stage research to global clinical validation.